Abstract
Endometriosis is a disease in which the lining of the endometrium is found outside of the uterus. Recent medical treatments for endometriosis have adverse effects, limiting their long-term use. Furthermore, the recurrence of the disease after the cessation of therapy is quite common, and most patients need to continue treatment to maintain a hypoestrogenic environment till conception. Notwithstanding recent advances in computational and chemical practices, traditional medicines are considered the most consistent sources for the discovery of new drugs. Numerous medicinal plants and plantderived compounds have been tested against gynecological disorders, mainly endometriosis. This review aimed to describe the pharmacological activity profile of the medicinal plants and their active ingredients and draw attention to the discovery of multitargeted drug molecules for rational therapy.
Keywords: Endometriosis, plants, phytochemicals, endometrium, cervix, glandular-cystic hyperplasia.
Graphical Abstract
[1]
Ergenoglu, A.M.; Yeniel, A.O.; Erbas, O.; Aktug, H.; Yildirim, N.; Ulukus, M.; Taskiran, D. Regression of endometrial implants by resveratrol in an experimentally induced endometriosis model in rats. Reprod. Sci., 2013, 20, 1230-1236.
[2]
Flower, A.; Liu, J.P.; Chen, S.; Lewith, G.; Little, P. Chinese herbal medicine for endometriosis. Cochrane Database Syst. Rev., 2009, CD006568.
[4]
Moraitis, S.; Taitzoglou, I.A.; Tsantarliotou, M.P.; Boscos, C.M.; Kaldrimidou, E.; Saratsis, P. Involvement of the plasminogen activation system in cow endometritis. Theriogenology, 2004, 61, 337-349.
[5]
Rogers, P.A.; D’Hooghe, T.M.; Fazleabas, A.; Gargett, C.E.; Giudice, L.C.; Montgomery, G.W.; Rombauts, L.; Salamonsen, L.A.; Zondervan, K.T. Priorities for endometriosis research: Recommendations from an international consensus workshop. Reprod. Sci., 2009, 16, 335-346.
[6]
Sharpe-Timms, K.L.; Young, S.L. Understanding endometriosis is the key to successful therapeutic management. Fertil. Steril., 2004, 81, 1201-1203.
[7]
Kyama, C.M.; Debrock, S.; Mwenda, J.M.; D’Hooghe, T.M. Potential involvement of the immune system in the development of endometriosis. Reprod. Biol. Endocrinol., 2003, 1, 123.
[8]
Schindler, A.E. Pathophysiology, diagnosis and treatment of endometriosis. Minerva Ginecol., 2004, 56, 419-435.
[9]
Taylor, R.N.; Lundeen, S.G.; Giudice, L.C. Emerging role of genomics in endometriosis research. Fertil. Steril., 2002, 78, 694-698.
[10]
Wenzl, R.; Kiesel, L.; Huber, J.C.; Wieser, F. Endometriosis: A genetic disease. Drugs Today (Barc), 2003, 39, 961-972.
[11]
Chegini, N. Peritoneal molecular environment, adhesion formation and clinical implication. Front. Biosci., 2002, 7, 91-115.
[12]
Gazvani, R.; Templeton, A. Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction, 2002, 123, 217-226.
[13]
Barcz, E.; Rozewska, E.S.; Kaminski, P.; Demkow, U.; Bobrowska, K.; Marianowski, L. Angiogenic activity and IL-8 concentrations in peritoneal fluid and sera in endometriosis. Int. J. Gynaecol. Obstet., 2002, 79, 229-235.
[14]
Drenkhahn, M.; Gescher, D.M.; Wolber, E.M.; Meyhoefer-Malik, A.; Malik, E. Expression of angiopoietin 1 and 2 in ectopic endometrium on the chicken chorioallantoic membrane. Fertil. Steril., 2004, 81(Suppl. 1), 869-875.
[15]
Osteen, K.G.; Bruner-Tran, K.L.; Ong, D.; Eisenberg, E. Paracrine mediators of endometrial matrix metalloproteinase expression: Potential targets for progestin-based treatment of endometriosis. Ann. N. Y. Acad. Sci., 2002, 955, 139-146.
[16]
Osteen, K.G.; Yeaman, G.R.; Bruner-Tran, K.L. Matrix metalloproteinases and endometriosis. Semin. Reprod. Med., 2003, 21, 155-164.
[17]
Ferrero, S.; Camerini, G.; Ragni, N.; Venturini, P.L.; Biscaldi, E.; Seracchioli, R.; Remorgida, V. Letrozole and norethisterone acetate in colorectal endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010, 150, 199-202.
[18]
Milingos, S.; Protopapas, A.; Drakakis, P.; Liapi, A.; Loutradis, D.; Kallipolitis, G.; Milingos, D.; Michalas, S. Laparoscopic management of patients with endometriosis and chronic pelvic pain. Ann. N. Y. Acad. Sci., 2003, 997, 269-273.
[19]
Oehmke, F.; Weyand, J.; Hackethal, A.; Konrad, L.; Omwandho, C.; Tinneberg, H.R. Impact of endometriosis on quality of life: A pilot study. Gynecol. Endocrinol., 2009, 25, 722-725.
[20]
Shi, J.; Ge, Z.B.Z.; Jin, Y.; Li, Y.D.I.; Zhou, J. Acupuncture improves the effects of chinese herbal medicine in treating endometriosis model rats. J. Anim. Plant Sci., 2013, 23, 298-303.
[21]
Sinaii, N.; Plumb, K.; Cotton, L.; Lambert, A.; Kennedy, S.; Zondervan, K.; Stratton, P. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil. Steril., 2008, 89, 538-545.
[22]
Anaf, V.; Simon, P.; El-Nakadi, I.; Fayt, I.; Simonart, T.; Buxant, F.; Noel, J.C. Hyperalgesia, nerve infiltration and nerve growth factor expression in deep adenomyotic nodules, peritoneal and ovarian endometriosis. Hum. Reprod., 2002, 17, 1895-1900.
[23]
Berkley, K.J.; Rapkin, A.J.; Papka, R.E. The pains of endometriosis. Science, 2005, 308, 1587-1589.
[24]
Mechsner, S.; Schwarz, J.; Thode, J.; Loddenkemper, C.; Salomon, D.S.; Ebert, A.D. Growth-associated protein 43-positive sensory nerve fibers accompanied by immature vessels are located in or near peritoneal endometriotic lesions. Fertil. Steril., 2007, 88, 581-587.
[25]
Wang, G.; Tokushige, N.; Markham, R.; Fraser, I.S. Rich innervation of deep infiltrating endometriosis. Hum. Reprod., 2009, 24, 827-834.
[26]
Nisolle, M.; Donnez, J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil. Steril., 1997, 68, 585-596.
[27]
Ballweg, M.L. Impact of endometriosis on women’s health: Comparative historical data show that the earlier the onset, the more severe the disease. Best Pract. Res. Clin. Obstet. Gynaecol., 2004, 18, 201-218.
[28]
van Langendonckt, A.; Casanas-Roux, F.; Dolmans, M.M.; Donnez, J. Potential involvement of hemoglobin and heme in the pathogenesis of peritoneal endometriosis. Fertil. Steril., 2002, 77, 561-570.
[29]
Vignali, M.; Infantino, M.; Matrone, R.; Chiodo, I.; Somigliana, E.; Busacca, M.; Vigano, P. Endometriosis: Novel etiopathogenetic concepts and clinical perspectives. Fertil. Steril., 2002, 78, 665-678.
[30]
Dziunycz, P.; Milewski, L.; Radomski, D.; Barcz, E.; Kaminski, P.; Roszkowski, P.I.; Malejczyk, J. Elevated ghrelin levels in the peritoneal fluid of patients with endometriosis: Associations with vascular endothelial growth factor (VEGF) and inflammatory cytokines. Fertil. Steril., 2009, 92, 1844-1849.
[31]
Neto, J.N.; Coelho, T.M.; Aguiar, G.C.; Carvalho, L.R.; de Araujo, A.G.; Girao, M.J.; Schor, E. Experimental endometriosis reduction in rats treated with Uncaria tomentosa (cat’s claw) extract. Eur. J. Obstet. Gynecol. Reprod. Biol., 2011, 154, 205-208.
[32]
Romm, A.; Burgess, I.; Winston, D.; Zick, S.M.; Crawford, A.M. Conditions of the reproductive organs. In: Botanical medicine for women’s health; Romm, A., Ed.; Churchill Livingstone: St. Louis, Missouri, 2010; p. 211.
[33]
Ling, F.W. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet. Gynecol., 1999, 93, 51-58.
[34]
Winkel, C.A. Evaluation and management of women with endometriosis. Obstet. Gynecol., 2003, 102, 397-408.
[35]
May, K.E.; Conduit-Hulbert, S.A.; Villar, J.; Kirtley, S.; Kennedy, S.H.; Becker, C.M. Peripheral biomarkers of endometriosis: A systematic review. Hum. Reprod. Update, 2010, 16, 651-674.
[36]
Gupta, S.; Agarwal, A.; Sekhon, L.; Krajcir, N.; Cocuzza, M.; Falcone, T. Serum and peritoneal abnormalities in endometriosis: Potential use as diagnostic markers. Minerva Ginecol., 2006, 58, 527-551.
[37]
Kennedy, S.; Bergqvist, A.; Chapron, C.; D’Hooghe, T.; Dunselman, G.; Greb, R.; Hummelshoj, L.; Prentice, A.; Saridogan, E. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum. Reprod., 2005, 20, 2698-2704.
[38]
Mol, B.W.; Bayram, N.; Lijmer, J.G.; Wiegerinck, M.A.; Bongers, M.Y.; van der Veen, F.; Bossuyt, P.M. The performance of CA-125 measurement in the detection of endometriosis: A meta-analysis. Fertil. Steril., 1998, 70, 1101-1108.
[39]
Eel, D.O.; Hornung, D.; Al-Hendy, A. Biomarkers of endometriosis. Expert Opin. Med. Diagn., 2008, 2, 741-752.
[40]
Becker, C.M.; D’Amato, R.J. Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc. Res., 2007, 74, 121-130.
[41]
Taylor, R.N.; Lebovic, D.I.; Mueller, M.D. Angiogenic factors in endometriosis. Ann. N. Y. Acad. Sci., 2002, 955, 89-100.
[42]
Bourlev, V.; Iljasova, N.; Adamyan, L.; Larsson, A.; Olovsson, M. Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. Fertil. Steril., 2010, 94, 52-57.
[43]
Matalliotakis, I.M.; Goumenou, A.G.; Koumantakis, G.E.; Athanassakis, I.; Dionyssopoulou, E.; Neonaki, M.A.; Vassiliadis, S. Expression of serum human leukocyte antigen and growth factor levels in a Greek family with familial endometriosis. J. Soc. Gynecol. Investig., 2003, 10, 118-121.
[44]
Xavier, P.; Belo, L.; Beires, J.; Rebelo, I.; Martinez-de-Oliveira, J.; Lunet, N.; Barros, H. Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch. Gynecol. Obstet., 2006, 273, 227-231.
[45]
Gagne, D.; Rivard, M.; Page, M.; Lepine, M.; Platon, C.; Shazand, K.; Hugo, P.; Gosselin, D. Development of a nonsurgical diagnostic tool for endometriosis based on the detection of endometrial leukocyte subsets and serum CA-125 levels. Fertil. Steril., 2003, 80, 876-885.
[46]
Eel, D.O.; Hornung, D.; Salem, H.T.; Khalifa, E.A.; El-Metwally, T.H.; Al-Hendy, A. Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol., 2008, 137, 240-246.
[47]
Pupo-Nogueira, A.; de Oliveira, R.M.; Petta, C.A.; Podgaec, S.; Dias, J.A., Jr; Abrao, M.S. Vascular endothelial growth factor concentrations in the serum and peritoneal fluid of women with endometriosis. Int. J. Gynaecol. Obstet., 2007, 99, 33-37.
[48]
Seppala, M.; Koistinen, H.; Koistinen, R.; Hautala, L.; Chiu, P.C.; Yeung, W.S. Glycodelin in reproductive endocrinology and hormone-related cancer. Eur. J. Endocrinol., 2009, 160, 121-133.
[49]
Julkunen, M.; Koistinen, R.; Sjoberg, J.; Rutanen, E.M.; Wahlstrom, T.; Seppala, M. Secretory endometrium synthesizes placental protein 14. Endocrinology, 1986, 118, 1782-1786.
[50]
Telimaa, S.; Kauppila, A.; Ronnberg, L.; Suikkari, A.M.; Seppala, M. Elevated serum levels of endometrial secretory protein PP14 in patients with advanced endometriosis. Suppression by treatment with danazol and high-dose medroxyprogesterone acetate. Am. J. Obstet. Gynecol., 1989, 161, 866-871.
[51]
Koninckx, P.R.; Riittinen, L.; Seppala, M.; Cornillie, F.J. CA-125 and placental protein 14 concentrations in plasma and peritoneal fluid of women with deeply infiltrating pelvic endometriosis. Fertil. Steril., 1992, 57, 523-530.
[52]
Becker, J.C.; Dummer, R.; Hartmann, A.A.; Burg, G.; Schmidt, R.E. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J. Immunol., 1991, 147, 4398-4401.
[53]
Wu, M.Y.; Ho, H.N. The role of cytokines in endometriosis. Am. J. Reprod. Immunol., 2003, 49, 285-296.
[54]
Kyama, C.M.; Mihalyi, A.; Gevaert, O.; Waelkens, E.; Simsa, P.; Van de Plas, R.; Meuleman, C.; De Moor, B.; D’Hooghe, T.M. Evaluation of endometrial biomarkers for semi-invasive diagnosis of endometriosis. Fertil. Steril., 2011, 95, 1338-1343.
[55]
Taniguchi, F.; Kaponis, A.; Izawa, M.; Kiyama, T.; Deura, I.; Ito, M.; Iwabe, T.; Adonakis, G.; Terakawa, N.; Harada, T. Apoptosis and endometriosis. Front. Biosci., 2011, 3, 648-662.
[56]
Kalu, E.; Sumar, N.; Giannopoulos, T.; Patel, P.; Croucher, C.; Sherriff, E.; Bansal, A. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. J. Obstet. Gynaecol. Res., 2007, 33, 490-495.
[57]
Socolov, R.; Butureanu, S.; Angioni, S.; Sindilar, A.; Boiculese, L.; Cozma, L.; Socolov, D. The value of serological markers in the diagnosis and prognosis of endometriosis: A prospective case-control study. Eur. J. Obstet. Gynecol. Reprod. Biol., 2011, 154, 215-217.
[58]
Darai, E.; Detchev, R.; Hugol, D.; Quang, N.T. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum. Reprod., 2003, 18, 1681-1685.
[59]
Bedaiwy, M.A.; Falcone, T.; Sharma, R.K.; Goldberg, J.M.; Attaran, M.; Nelson, D.R.; Agarwal, A. Prediction of endometriosis with serum and peritoneal fluid markers: A prospective controlled trial. Hum. Reprod., 2002, 17, 426-431.
[60]
Ohata, Y.; Harada, T.; Miyakoda, H.; Taniguchi, F.; Iwabe, T.; Terakawa, N. Serum interleukin-8 levels are elevated in patients with ovarian endometrioma. Fertil. Steril., 2008, 90, 994-999.
[61]
Pizzo, A.; Salmeri, F.M.; Ardita, F.V.; Sofo, V.; Tripepi, M.; Marsico, S. Behaviour of cytokine levels in serum and peritoneal fluid of women with endometriosis. Gynecol. Obstet. Invest., 2002, 54, 82-87.
[62]
Al-Jefout, M.; Andreadis, N.; Tokushige, N.; Markham, R.; Fraser, I. A pilot study to evaluate the relative efficacy of endometrial biopsy and full curettage in making a diagnosis of endometriosis by the detection of endometrial nerve fibers. Am. J. Obstet. Gynecol., 2007, 197(578), e1-e4.
[63]
Al-Jefout, M.; Dezarnaulds, G.; Cooper, M.; Tokushige, N.; Luscombe, G.M.; Markham, R.; Fraser, I.S. Diagnosis of endometriosis by detection of nerve fibres in an endometrial biopsy: A double blind study. Hum. Reprod., 2009, 24, 3019-3024.
[64]
Bokor, A.; Kyama, C.M.; Vercruysse, L.; Fassbender, A.; Gevaert, O.; Vodolazkaia, A.; De Moor, B.; Fulop, V.; D’Hooghe, T. Density of small diameter sensory nerve fibres in endometrium: A semi-invasive diagnostic test for minimal to mild endometriosis. Hum. Reprod., 2009, 24, 3025-3032.
[65]
Tokushige, N.; Markham, R.; Russell, P.; Fraser, I.S. High density of small nerve fibres in the functional layer of the endometrium in women with endometriosis. Hum. Reprod., 2006, 21, 782-787.
[66]
Tokushige, N.; Markham, R.; Russell, P.; Fraser, I.S. Different types of small nerve fibers in eutopic endometrium and myometrium in women with endometriosis. Fertil. Steril., 2007, 88, 795-803.
[67]
Barcena de Arellano, M.L.; Arnold, J.; Sacher, F.; Blochle, M.; Staube, M.; Bartley, J.; Vercellino, G.F.; Chiantera, V.; Schneider, A.; Mechsner, S. Eutopic endometrium from women with endometriosis does not exhibit neurotrophic properties. J. Neuroimmunol., 2012, 249, 49-55.
[68]
Zhang, X.; Lu, B.; Huang, X.; Xu, H.; Zhou, C.; Lin, J. Endometrial nerve fibers in women with endometriosis, adenomyosis, and uterine fibroids. Fertil. Steril., 2009, 92, 1799-1801.
[69]
Zhang, X.; Lu, B.; Huang, X.; Xu, H.; Zhou, C.; Lin, J. Innervation of endometrium and myometrium in women with painful adenomyosis and uterine fibroids. Fertil. Steril., 2010, 94, 730-737.
[70]
Somigliana, E.; Vigano, P.; Parazzini, F.; Stoppelli, S.; Giambattista, E.; Vercellini, P. Association between endometriosis and cancer: A comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol. Oncol., 2006, 101, 331-341.
[71]
Crosignani, P.; Olive, D.; Bergqvist, A.; Luciano, A. Advances in the management of endometriosis: An update for clinicians. Hum. Reprod. Update, 2006, 12, 179-189.
[72]
Parazzini, F.; Di Cintio, E.; Chatenoud, L.; Moroni, S.; Ardovino, I.; Struzziero, E.; Falsetti, L.; Bianchi, A.; Bracco, G.; Pellegrini, A.; Bertulessi, C.; Romanini, C.; Zupi, E.; Massobrio, M.; Guidetti, D.; Troiano, L.; Beretta, P.; Franchi, M. Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: A randomized trial. Eur. J. Obstet. Gynecol. Reprod. Biol., 2000, 88, 11-14.
[73]
Vercellini, P.; Trespidi, L.; Colombo, A.; Vendola, N.; Marchini, M.; Crosignani, P.G. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil. Steril., 1993, 60, 75-79.
[74]
Anderson, J.J.; Anthony, M.; Messina, M.; Garne, S.C. Effects of phyto-oestrogens on tissues. Nutr. Res. Rev., 1999, 12, 75-116.
[75]
Cottreau, C.M.; Ness, R.B.; Modugno, F.; Allen, G.O.; Goodman, M.T. Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer. Clin. Cancer Res., 2003, 9, 5142-5144.
[76]
Vasilakis, C.; Jick, H.; del Mar Melero-Montes, M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet, 1999, 354, 1610-1611.
[77]
Allen, C.; Hopewell, S.; Prentice, A. Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst. Rev., 2005, CD004753.
[78]
Amsterdam, L.L.; Gentry, W.; Jobanputra, S.; Wolf, M.; Rubin, S.D.; Bulun, S.E. Anastrazole and oral contraceptives: A novel treatment for endometriosis. Fertil. Steril., 2005, 84, 300-304.
[79]
Lebovic, D.I.; Mueller, M.D.; Taylor, R.N. Immunobiology of endometriosis. Fertil. Steril., 2001, 75, 1-10.
[80]
Cobellis, L.; Razzi, S.; De Simone, S.; Sartini, A.; Fava, A.; Danero, S.; Gioffre, W.; Mazzini, M.; Petraglia, F. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol., 2004, 116, 100-102.
[81]
Chwalisz, K.; Perez, M.C.; Demanno, D.; Winkel, C.; Schubert, G.; Elger, W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr. Rev., 2005, 26, 423-438.
[82]
Mori, T.; Yamasaki, S.; Masui, F.; Matsuda, M.; Sasabe, H.; Zhou, Y.F. Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice. Exp. Biol. Med. (Maywood), 2001, 226, 429-433.
[83]
Barrier, B.F.; Bates, G.W.; Leland, M.M.; Leach, D.A.; Robinson, R.D.; Propst, A.M. Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons. Fertil. Steril., 2004, 81(Suppl. 1), 775-779.
[84]
Nap, A.W.; Dunselman, G.A.; Griffioen, A.W.; Mayo, K.H.; Evers, J.L.; Groothuis, P.G. Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil. Steril., 2005, 83, 793-795.
[85]
Badawy, S.Z.; Etman, A.; Cuenca, V.; Montante, A.; Kaufman, L. Effect of interferon alpha-2b on endometrioma cells in vitro. Obstet. Gynecol., 2001, 98, 417-420.
[86]
Stephens, L.; Whitehouse, J.; Polley, M. Western herbal medicine, epigenetics, and endometriosis. J. Altern. Complement. Med., 2013, 19, 853-859.
[87]
Varma, R.; Rollason, T.; Gupta, J.K.; Maher, E.R. Endometriosis and the neoplastic process. Reproduction, 2004, 127, 293-304.
[88]
Trabert, B.; Peters, U.; De Roos, A.J.; Scholes, D.; Holt, V.L. Diet and risk of endometriosis in a population-based case-control study. Br. J. Nutr., 2011, 105, 459-467.
[89]
Vercellini, P.; Trespidi, L.; De Giorgi, O.; Cortesi, I.; Parazzini, F.; Crosignani, P.G. Endometriosis and pelvic pain: Relation to disease stage and localization. Fertil. Steril., 1996, 65, 299-304.
[90]
Parazzini, F.; Chiaffarino, F.; Surace, M.; Chatenoud, L.; Cipriani, S.; Chiantera, V.; Benzi, G.; Fedele, L. Selected food intake and risk of endometriosis. Hum. Reprod., 2004, 19, 1755-1759.
[91]
Jackson, L.W.; Schisterman, E.F.; Dey-Rao, R.; Browne, R.; Armstrong, D. Oxidative stress and endometriosis. Hum. Reprod., 2005, 20, 2014-2020.
[92]
Mier-Cabrera, J.; Aburto-Soto, T.; Burrola-Mendez, S.; Jimenez-Zamudio, L.; Tolentino, M.C.; Casanueva, E.; Hernandez-Guerrero, C. Women with endometriosis improved their peripheral antioxidant markers after the application of a high antioxidant diet. Reprod. Biol. Endocrinol., 2009, 7, 54.
[93]
Britton, J.A.; Westhoff, C.; Howe, G.; Gammon, M.D. Diet and benign ovarian tumors (United States). Cancer Causes Control, 2000, 11, 389-401.
[94]
Rosado, J.L.; Bourges, H.; Saint-Martin, B. Vitamin and mineral deficiency in Mexico. A critical review of the state of the art. II. Vitamin deficiency. Salud Publica Mex., 1995, 37, 452-461.
[95]
Lukic, M.; Guha, N.; Licaj, I.; van den Brandt, P.A.; Stayner, L.T.; Tavani, A.; Weiderpass, E. Coffee drinking and the risk of endometrial cancer: An updated meta-analysis of observational studies. Nutr. Cancer, 2018, 70, 513-528.
[96]
Hernandez-Avila, M.; Romieu, I.; Parra, S.; Hernandez-Avila, J.; Madrigal, H.; Willett, W. Validity and reproducibility of a food frequency questionnaire to assess dietary intake of women living in Mexico City. Salud Publica Mex., 1998, 40, 133-140.
[97]
Ferrini, R.L.; Barrett-Connor, E. Caffeine intake and endogenous sex steroid levels in postmenopausal women. The rancho bernardo study. Am. J. Epidemiol., 1996, 144, 642-644.
[99]
DeCherney, A. Physiologic and pharmacologic effects of estrogen and progestins on bone. J. Reprod. Med., 1993, 38, 1007-1014.
[100]
Chajes, V.; Thiebaut, A.C.; Rotival, M.; Gauthier, E.; Maillard, V.; Boutron-Ruault, M.C.; Joulin, V.; Lenoir, G.M.; Clavel-Chapelon, F. Association between serum trans-monounsaturated fatty acids and breast cancer risk in the E3N-EPIC study. Am. J. Epidemiol., 2008, 167, 1312-1320.
[101]
Frackiewicz, E. J. Endometriosis: An overview of the disease and its treatment. J. Am. Pharm. Assoc. (Wash.), 2000, 40, 645-657.
[102]
Valle, R.F.; Sciarra, J. J. Endometriosis: Treatment strategies. Ann. N. Y. Acad. Sci., 2003, 997, 229-239.
[103]
Vercellini, P.; Fedele, L.; Pietropaolo, G.; Frontino, G.; Somigliana, E.; Crosignani, P.G. Progestogens for endometriosis: Forward to the past. Hum. Reprod. Update, 2003, 9, 387-396.
[104]
Calder, P.C. N-3 polyunsaturated fatty acids and inflammation: From molecular biology to the clinic. Lipids, 2003, 38, 343-352.
[105]
Gazvani, M.R.; Smith, L.; Haggarty, P.; Fowler, P.A.; Templeton, A. High omega-3: Omega-6 fatty acid ratios in culture medium reduce endometrial-cell survival in combined endometrial gland and stromal cell cultures from women with and without endometriosis. Fertil. Steril., 2001, 76, 717-722.
[106]
Missmer, S.A.; Chavarro, J.E.; Malspeis, S.; Bertone-Johnson, E.R.; Hornstein, M.D.; Spiegelman, D.; Barbieri, R.L.; Willett, W.C.; Hankinson, S.E. A prospective study of dietary fat consumption and endometriosis risk. Hum. Reprod., 2010, 25, 1528-1535.
[108]
Shukla, A. A Case study of medicinal plants used by local women for gynecological disorders in Karaikal (U.T. of Puducherry). J. Phytol., 2012, 4, 9-12.
[109]
Shukla, R.; Chakravarty, M.; Gautam, M.P. Indigenous medicine used for treatment of gynecological disorders by tribal of chhattisgarh, India. J. Med. Plants Res., 2008, 2, 356-360.
[110]
Behera, K.K. Plants used for gynecological disorders by tribals of Mayurbhanj district, Orissa, India. Ethnobot. Leaflets, 2006, 2006, 15.
[111]
Sahu, P.K. Plants used by Gond and Baiga women in ethnogynaecological disorders in Achanakmar wild life sanctuary, Bilaspur. CG Int. J. Pharm. Life Sci., 2011, 2, 559-561.
[112]
Goswami, P.K.; Khale, A.; Ogale, S. Natural remedies for polycystic ovarian syndrome (PCOS): A review. Int. J. Pharm. Phytopharm. Res., 2017, 1, 396-402.
[113]
Wieser, F.; Cohen, M.; Gaeddert, A.; Yu, J.; Burks-Wicks, C.; Berga, S.L.; Taylor, R.N. Evolution of medical treatment for endometriosis: Back to the roots? Hum. Reprod. Update, 2007, 13, 487-499.
[114]
Wieser, F.; Yu, J.; Park, J.; Gaeddert, A.; Cohen, M.; Vigne, J.L.; Taylor, R.N. A botanical extract from channel flow inhibits cell proliferation, induces apoptosis, and suppresses CCL5 in human endometriotic stromal cells. Biol. Reprod., 2009, 81, 371-377.
[115]
Carey, K.B.; Purnine, D.M.; Maisto, S.A.; Carey, M.P. Assessing readiness to change substance abuse: A critical review of instruments. Clin. Psychol. Sci. Pract., 1999, 6, 245-266.
[116]
Zheng, W.; Cao, L.; Xu, Z.; Ma, Y.; Liang, X. Anti-angiogenic alternative and complementary medicines for the treatment of endometriosis: A review of potential molecular mechanisms. Evid. Based Complement. Alternat. Med., 2018, 2018, 4128984.
[117]
Zheng, Y.; Liu, X.; Guo, S.W. Therapeutic potential of andrographolide for treating endometriosis. Hum. Reprod., 2012, 27, 1300-1313.
[118]
Saltan, G.; Suntar, I.; Ozbilgin, S.; Ilhan, M.; Demirel, M.A.; Oz, B.E.; Keles, H.; Akkol, E.K. Viburnum opulus L.: A remedy for the treatment of endometriosis demonstrated by rat model of surgically-induced endometriosis. J. Ethnopharmacol., 2016, 193, 450-455.
[119]
Kobayashi, T.; Robinson, J.M.; Seguchi, H. Identification of intracellular sites of superoxide production in stimulated neutrophils. J. Cell Sci., 1998, 111(Pt 1), 81-91.
[120]
Upton, R. Dong gui root: Angelica sinensis (Oliv.) Diels: Standards of analysis, quality control, and therapeutics, American Herbal Pharmacopoeia and therapetic compendium; American Herbal Pharmacopoeia: Scotts Valley, CA, 2003.
[121]
Wang, S.R.; Guo, Z.Q.; Liao, J.Z. Experimental study on effects of 18 kinds of Chinese herbal medicine for synthesis of thromboxane A2 and PGI2. Chin. J. Integr. Med., 1993, 13, 167-170.
[122]
Ivanov, V.; Ivanova, S.; Kalinovsky, T.; Niedzwiecki, A.; Rath, M. Plant-derived micronutrients suppress monocyte adhesion to cultured human aortic endothelial cell layer by modulating its extracellular matrix composition. J. Cardiovasc. Pharmacol., 2008, 52, 55-65.
[123]
Baytop, T. Therapy with medicinal plants in Turkey (past and present), 2nd ed; Nobel Tıp Kitabevleri: Istanbul, 1999.
[124]
Yesilada, E.; Honda, G.; Sezik, E.; Tabata, M.; Fujita, T.; Tanaka, T.; Takeda, Y.; Takaishi, Y. Traditional medicine in Turkey. V. Folk medicine in the inner Taurus Mountains. J. Ethnopharmacol., 1995, 46, 133-152.
[125]
Demirel, M.A.; Suntar, I.; Ilhan, M.; Keles, H.; Kupeli Akkol, E. Experimental endometriosis remission in rats treated with Achillea biebersteinii Afan.: Histopathological evaluation and determination of cytokine levels. Eur. J. Obstet. Gynecol. Reprod. Biol., 2014, 175, 172-177.
[126]
Sharma, M.; Schoop, R.; Hudson, J.B. Echinacea as an antiinflammatory agent: The influence of physiologically relevant parameters. Phytother. Res., 2009, 23, 863-867.
[127]
Pareek, A.; Suthar, M.; Rathore, G.S.; Bansal, V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn. Rev., 2011, 5, 103-110.
[128]
Hisa, T.; Kimura, Y.; Takada, K.; Suzuki, F.; Takigawa, M. Shikonin, an ingredient of Lithospermum erythrorhizon, inhibits angiogenesis in vivo and in vitro. Anticancer Res., 1998, 18, 783-790.
[129]
Yuan, D.P.; Gu, L.; Long, J.; Chen, J.; Ni, J.; Qian, N.; Shi, Y.L. Shikonin reduces endometriosis by inhibiting RANTES secretion and mononuclear macrophage chemotaxis. Exp. Ther. Med., 2014, 7, 685-690.
[130]
Simmen, U.; Burkard, W.; Berger, K.; Schaffner, W.; Lundstrom, K. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system. J. Recept. Signal Transduct. Res., 1999, 19, 59-74.
[131]
Murphy, P.A.; Kern, S.E.; Stanczyk, F.Z.; Westhoff, C.L. Interaction of St. John’s Wort with oral contraceptives: Effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception, 2005, 71, 402-408.
[132]
Azarnia, M.; Ejtemaee-Mehr, S.; Ansari, A.S.A. Effects of Vitex agnus castus on mice fetus development. Acta Med. Iran., 2007, 45, 263-270.
[133]
Mayo, J.L. Black cohosh and chasteberry: Herbs valued by women for centuries. Clin. Nutr. Insights, 1998, 6, 1-5.
[134]
Amuthan, A.; Anandh, S.; Musharraf, S.; Agarwal, N.; Devi, V.; Shenoy, R.P.; Nayal, B. Effect of Notchi kudineer (Vitex negundo aqueous extract) on surgically induced endometriosis in Sprague Dawley rats. Int. J. Pharm., 2015, 4, 35-43.
[135]
Das, S.; Parveen, S.; Kundra, C.P.; Pereira, B.M. Reproduction in male rats is vulnerable to treatment with the flavonoid-rich seed extracts of Vitex negundo. Phytother. Res., 2004, 18, 8-13.
[136]
Tandon, V.R.; Gupta, R.K. Anti-inflammatory activity and mechanism of action of Vitex negundo Linn. Int. J. Pharm., 2006, 2, 303-308.
[137]
Bensky, D.; Clavey, S.; Stoger, E. Chinese Herbal Medicine: Materia Medica3rd ed. ed; Eastland Press: Seattle, 2004.
[138]
Holmes, P. The energetics of western herbs: Treatment strategies integrating western and oriental herbal medicine3rd ed. ed; Snow Lotus Press: Boulder,, 1998.
[139]
Tanaka, T.; Umesaki, N.; Mizuno, K.; Fujino, Y.; Ogita, S. Anti-endometrial IgM autoantibodies in endometriotic patients: A preliminary study. Clin. Exp. Obstet. Gynecol., 2000, 27, 133-137.
[140]
Trickey, R. Women, hormones and the menstrual cycle. Herbal and medical solutions from adolescence to menopause; Allen and Unwin: St Leonards, Australia, 1998.
[141]
Kupeli Akkol, E.; Demirel, M.A.; Bahadir Acikara, O.; Suntar, I.; Ergene, B.; Ilhan, M.; Ozbilgin, S.; Saltan, G.; Keles, H.; Tekin, M. Phytochemical analyses and effects of Alchemilla mollis (Buser) Rothm. and Alchemilla persica Rothm. in rat endometriosis model. Arch. Gynecol. Obstet., 2015, 292, 619-628.
[142]
Wichtl, M. Herbal drugs and phytopharmaceuticals: A handbook for practice on a scientific basis4th ed. ed; Medpharm: Stuttgart,, 2004.
[143]
Ernst, E.; Pittler, M.H. Efficacy of ginger for nausea and vomiting: A systematic review of randomized clinical trials. Br. J. Anaesth., 2000, 84, 367-371.
[144]
Aggarwal, B.B.; Bhardwaj, A.; Aggarwal, R.S.; Seeram, N.P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res., 2004, 24, 2783-2840.
[145]
Chen, D.; Wan, S.B.; Yang, H.; Yuan, J.; Chan, T.H.; Dou, Q.P. EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv. Clin. Chem., 2011, 53, 155-177.
[146]
Cucciolla, V.; Borriello, A.; Oliva, A.; Galletti, P.; Zappia, V.; Della Ragione, F. Resveratrol: From basic science to the clinic. Cell Cycle, 2007, 6, 2495-2510.
[147]
Khan, N.; Mukhtar, H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett., 2008, 269, 269-280.
[148]
Qiao, Y.; Cao, J.; Xie, L.; Shi, X. Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells. Arch. Pharm. Res., 2009, 32, 1309-1315.
[149]
Rao, S.D.; Pagidas, K. Epigallocatechin-3-gallate, a natural polyphenol, inhibits cell proliferation and induces apoptosis in human ovarian cancer cells. Anticancer Res., 2010, 30, 2519-2523.
[150]
Zaveri, N.T. Green tea and its polyphenolic catechins: Medicinal uses in cancer and noncancer applications. Life Sci., 2006, 78, 2073-2080.
[151]
Zhang, D.; Al-Hendy, M.; Richard-Davis, G.; Montgomery-Rice, V.; Rajaratnam, V.; Al-Hendy, A. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil. Steril., 2010, 94, 1887-1893.
[152]
Zhang, D.; Al-Hendy, M.; Richard-Davis, G.; Montgomery-Rice, V.; Sharan, C.; Rajaratnam, V.; Khurana, A.; Al-Hendy, A. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am. J. Obstet. Gynecol., 2010, 202, 289 e1-9.
[153]
Bruner-Tran, K.L.; Osteen, K.G.; Taylor, H.S.; Sokalska, A.; Haines, K.; Duleba, A.J. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol. Reprod., 2011, 84, 106-112.
[154]
Xu, H.; Becker, C.M.; Lui, W.T.; Chu, C.Y.; Davis, T.N.; Kung, A.L.; Birsner, A.E.; D’Amato, R.J.; Wai, Man. G.C.; Wang, C.C. Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo. Fertil. Steril., 2011, 96, 1021-1028.
[155]
Wang, C.C.; Xu, H.; Man, G.C.; Zhang, T.; Chu, K.O.; Chu, C.Y.; Cheng, J.T.; Li, G.; He, Y.X.; Qin, L.; Lau, T.S.; Kwong, J.; Chan, T.H. Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) as a potent anti-angiogenesis agent for endometriosis in mice. Angiogenesis, 2013, 16, 59-69.
[156]
Xu, H.; Lui, W.T.; Chu, C.Y.; Ng, P.S.; Wang, C.C.; Rogers, M.S. Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. Hum. Reprod., 2009, 24, 608-618.
[157]
Laschke, M.W.; Schwender, C.; Scheuer, C.; Vollmar, B.; Menger, M.D. Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo. Hum. Reprod., 2008, 23, 2308-2318.
[158]
Ricci, A.G.; Olivares, C.N.; Bilotas, M.A.; Baston, J.I.; Singla, J.J.; Meresman, G.F.; Baranao, R.I. Natural therapies assessment for the treatment of endometriosis. Hum. Reprod., 2013, 28, 178-188.
[159]
Chen, R.; Liu, H.; Jiang, R.; Li, X.; Qu, Y.F. Effect of traditional Chinese medicine (Daqiqi Tang) on expressions of VEGF and MMP-9 in endometriosis rats. Reprod. Contracept., 2010, 30, 1145-1148.
[160]
Zhang, Q.; Fang, Y.; Wang, L.; Chen, R. Effect of Da Qiqi decoction on expression of P450 and COX-2 in endometriosis of rats. J. Third Mil. Med. Univ., 2012, 34, 2167-2171.
[161]
Arablou, T.; Kolahdouz-Mohammadi, R. Curcumin and endome-triosis: Review on potential roles and molecular mechanisms. Biomed. Pharmacother., 2018, 97, 91-97.
[162]
Kim, K.H.; Lee, E.N.; Park, J.K.; Lee, J.R.; Kim, J.H.; Choi, H.J.; Kim, B.S.; Lee, H.W.; Lee, K.S.; Yoon, S. Curcumin attenuates TNF-alpha-induced expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and proinflammatory cytokines in human endometriotic stromal cells. Phytother. Res., 2012, 26, 1037-1047.
[163]
Jana, S.; Rudra, D.S.; Paul, S.; Snehasikta, S. Curcumin delays endometriosis development by inhibiting MMP-2 activity. Indian J. Biochem. Biophys., 2012, 49, 342-348.
[164]
Jana, S.; Paul, S.; Swarnakar, S. Curcumin as anti-endometriotic agent: Implication of MMP-3 and intrinsic apoptotic pathway. Biochem. Pharmacol., 2012, 83, 797-804.
[165]
Swarnakar, S.; Paul, S. Curcumin arrests endometriosis by downregulation of matrix metalloproteinase-9 activity. Indian J. Biochem. Biophys., 2009, 46, 59-65.
[166]
Zhang, Y.; Cao, H.; Yu, Z.; Peng, H.Y.; Zhang, C.J. Curcumin inhibits endometriosis endometrial cells by reducing estradiol production. Iran. J. Reprod. Med., 2013, 11, 415-422.
[167]
Jana, S.K.; Chakravarty, B.; Chaudhury, K. Letrozole and curcumin loaded-PLGA nanoparticles: A therapeutic strategy for endometriosis. J. Nanomed Biotherap Discov., 2014, 4, 123.
[168]
Cheng, W.; Chen, L.; Yang, S.; Han, J.; Zhai, D.; Ni, J.; Yu, C.; Cai, Z. Puerarin suppresses proliferation of endometriotic stromal cells partly via the MAPK signaling pathway induced by 17ss-estradiol-BSA. PLoS One, 2012, 7, e45529.
[169]
Wang, D.; Liu, Y.; Han, J.; Zai, D.; Ji, M.; Cheng, W.; Xu, L.; Yang, L.; He, M.; Ni, J.; Cai, Z.; Yu, C. Puerarin suppresses invasion and vascularization of endometriosis tissue stimulated by 17beta-estradiol. PLoS One, 2011, 6, e25011.
[170]
Long, J.R.; Li, Z. Ginsenoside Rg3 in combination with surgery in patients with stage III-IV endometriosis: A clinical control trial. Chinese Remed. Clin., 2012, 12, 720-724.
[171]
Li, Z.; Zhi, M.C.; Li, X.L. Control study of Ginsenosides and Gestrinone on the treatment of endometriosis rats. Chin. J. Obstet. Gynecol., 2007, 42, 417-418.
[172]
Song, Z.Y.; Li, Z.; Zhi, M.C.; Jiang, Y.H. The observation of inhibition effect of Ginsenoside Rg3 on endometriosis rats model. Chinese Remed. Clin., 2006, 6, 255-256.
[173]
Maia, H., Jr; Haddad, C.; Pinheiro, N.; Casoy, J. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int. J. Womens Health, 2012, 4, 543-549.
[174]
Rudzitis-Auth, J.; Menger, M.D.; Laschke, M.W. Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis. Hum. Reprod., 2013, 28, 1339-1347.
[175]
Herington, J.L.; Crispens, M.A.; Carvalho-Macedo, A.C.; Camargos, A.F.; Lebovic, D.I.; Bruner-Tran, K.L.; Osteen, K.G. Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis. Fertil. Steril., 2011, 95(4), 1295-301.e1.
[176]
Taylor, H.S.; Osteen, K.G.; Bruner-Tran, K.L.; Lockwood, C.J.; Krikun, G.; Sokalska, A.; Duleba, A.J. Novel therapies targeting endometriosis. Reprod. Sci., 2011, 18, 814-823.
[177]
Jin, Z.; Huang, J.; Zhu, Z. Baicalein reduces endometriosis by suppressing the viability of human endometrial stromal cells through the nuclear factor-kappaB pathway in vitro. Exp. Ther. Med., 2017, 14, 2992-2998.
[178]
Di Paola, R.; Fusco, R.; Gugliandolo, E.; Crupi, R.; Evangelista, M.; Granese, R.; Cuzzocrea, S. Co-micronized palmitoylethano-lamide/polydatin treatment causes endometriotic lesion regression in a rodent model of surgically induced endometriosis. Front. Pharmacol., 2016, 7, 382.
[179]
Lin, L.G.; Liu, Q.Y.; Ye, Y. Naturally occurring homoiso-flavonoids and their pharmacological activities. Planta Med., 2014, 80, 1053-1066.
[180]
Cosar, E.; Mamillapalli, R.; Moridi, I.; Duleba, A.; Taylor, H.S. Serum microRNA biomarkers regulated by simvastatin in a primate model of endometriosis. Reprod. Sci., 2018, 1933719118765971.
[181]
Rudzitis-Auth, J.; Korbel, C.; Scheuer, C.; Menger, M.D.; Laschke, M.W. Xanthohumol inhibits growth and vascularization of developing endometriotic lesions. Hum. Reprod., 2012, 27, 1735-1744.
[182]
Mills, S.; Bone, K. Principle and practice of phytotherapy; Churchill Livingstone: London, 2000.
[183]
Micozzi, M.S.; Dog, T.L. Women’s Health in Complementary and Integrative Medicine: A Clinical Guide; Elsevier Health Sciences, 2004.
[184]
Ilhan, M.; Suntar, I.; Demirel, M.A.; Yesilada, E.; Keles, H.; Kupeli Akkol, E. A mixture of St. John’s wort and sea buckthorn oils regresses endometriotic implants and affects the levels of inflammatory mediators in peritoneal fluid of the rat: A surgically induced endometriosis model. Taiwan. J. Obstet. Gynecol., 2016, 55, 786-790.
Related Books
Localized Micro/Nanocarriers for Programmed and On-Demand Controlled Drug Release
Mixed Polymeric Micelles for Osteosarcoma Therapy: Development and Characterization
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Nanomaterials: Evolution and Advancement towards Therapeutic Drug Delivery (Part II)
Nanomaterials: Evolution and Advancement Towards Therapeutic Drug Delivery (Part I)
Article Metrics
67
11